[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pcos-polycystic-ovary-syndrome-of-bilateral-ovaries\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pcos-polycystic-ovary-syndrome-of-bilateral-ovaries":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,66,96,123,145,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100606974","phase-2-effects-of-adding-quercetin-or-alpha-lipoic-acid-to-usual-care-on-symptoms-and-blood-markers-in-iraqi-women-with-polycystic-ovary-syndrome-100606974",false,"NCT07182526","Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome","Impact of Adding Quercetin or Alpha Lipoic Acid as an Adjuvant Therapy on Clinical and Biochemical Outcomes in a Sample of Iraqi PCOS Patients","Inclusion Criteria:\n\n* • Newly diagnosed patients should be at reproductive aged from 18-40 years.\n\n  * Patients diagnosed with presence of micro polycystic ovaries at ultrasound.\n  * Oligomenorrhea with inter-menstrual intervals longer than 35 days.\n  * Clinical or biochemical signs of hyperandrogenism (acne, hirsutism).\n  * Normal PRL levels.\n\nExclusion Criteria:\n\n* • Presence of enzymatic adrenal deficiency and\u002For other endocrine disease, including diabetes.\n\n  * Other comorbidities (such as hypertension, cardiovascular disease, or hormonal dysfunction).\n  * Women who used oral contraceptives, hormonal therapy, or anti-lipidemic drugs.\n  * Pregnant women.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.",[26],"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","RECRUITING","2025-09-18",{"date":30,"type":31},"2025-09-19","ACTUAL",{"date":33,"type":20},"2025-09-20",{"date":35,"type":20},"2026-05-01",{"name":37,"class":38},"Al-Mustansiriyah University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":39},"100607491","evaluation-of-fibromyalgia-frequency-and-pain-parameters-in-women-with-polycystic-ovary-syndrome-100607491","NCT07189247","Evaluation of Fibromyalgia Frequency and Pain Parameters in Women With Polycystic Ovary Syndrome","Evaluation of Fibromyalgia Frequency and Pain Parameters in Women With Polycystic Ovary Syndrome: A Prospective Single-Blind Study","Inclusion Criteria:\n\n1. Women aged 18-40\n2. Those diagnosed with Polycystic Ovary Syndrome by a Gynecologist and Obstetrician (according to the Rotterdam Criteria)\n3. Those who agreed to participate in the study and signed the informed consent form\n\nExclusion Criteria:\n\n1. Patients with underlying uterine or adnexal pathologies (endometrial polyps, adenomyosis, uterine fibroids, adnexal masses, etc.) identified by ultrasound\n2. Patients with previous pelvic surgery\n3. Secondary causes of hirsutism and oligomenorrhea (non-classical congenital adrenal hyperplasia, Cushing's syndrome, hypothyroidism, prolactinoma, androgen-synthesizing tumor)\n4. Pregnant women\n5. Patients with a history of muscular or rheumatological diseases\n6. Patients with uncontrolled diabetes\n7. Patients with severe psychiatric illnesses or a history of psychiatric medication\u002Fsubstance abuse",true,"FEMALE","40 Years",{"count":51,"type":20},140,"OBSERVATIONAL","The primary objective was to determine the prevalence of fibromyalgia in women with PCOS and to examine the relationship between fibromyalgia and psychological status (depression and anxiety). Secondary objectives were to explore the potential link between fibromyalgia and insulin resistance, taking into account phenotypic differences. To assess the relationship between fibromyalgia severity and quality of life and pressure pain threshold measurements. To analyze the impact of pain and mood disorders on PCOS phenotypes and to demonstrate the role of insulin resistance in predicting fibromyalgia.\n\nParticipants will be women aged 18-40 diagnosed with PCOS according to the Rotterdam criteria, and a healthy control group of a similar age. When making a PCOS diagnosis, clinical (hirsutism, acne, menstrual irregularity), biochemical (free testosterone, DHEAS, androstenedione, etc.), and ultrasonographic (polycystic ovary morphology) findings will be evaluated. The control group will consist of healthy volunteers presenting with gynecological complaints other than PCOS and without chronic diseases.\n\nExamination and Assessment Process Obstetrics and Gynecology Outpatient Clinic: PCOS diagnosis, demographic data, biochemical tests (glucose, insulin, HOMA-IR, etc.), and phenotyping.\n\nPhysical Therapy and Rehabilitation: Application of the 2016 ACR fibromyalgia criteria in a single-blind trial, including measurement of pressure pain threshold (algometer), fibromyalgia severity scale, and recording of Fibromyalgia Impact Questionnaire scores.\n\nPsychological Assessment The HADS (Hospital Anxiety and Depression Scale) will be administered to assess depression and anxiety levels.\n\nScores obtained will be compared with fibromyalgia diagnosis and PCOS phenotypes to examine the influence of psychological factors on pain perception.",[55,26],"Fibromyalgia","NOT_YET_RECRUITING","2025-09-16",{"date":59,"type":31},"2025-09-23",{"date":61,"type":20},"2025-11-01",{"date":63,"type":20},"2026-11-01",{"name":65,"class":38},"Ufuk University",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":48,"minAge":73,"maxAge":49,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":39},"100519258","best-treatment-for-women-with-both-polycystic-ovary-syndrome-pcos-and-subclinical-hypothyroidism-100519258","NCT06041204","Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism","Letrozole Alone vs. Letrozole Plus Levothyroxine for Ovulation Induction in Infertile Women With Both (Polycystic Ovary Syndrome) PCOS and Sub-clinical Hypothyroidism.","Inclusion Criteria:\n\nAge between 20-40 years\n\nBMI between 18-35 kg\u002Fm2\n\nMeet diagnostic criteria for PCOS based on the Rotterdam consensus criteria and ESHRE\u002FASRM modifications (2018):\n\nOligo- and\u002For anovulation Clinical and\u002For biochemical signs of hyperandrogenism Polycystic ovaries on ultrasound\n\nSubclinical hypothyroidism defined as TSH level between 5-10 mIU\u002FL with normal free T4\n\nInfertility duration ≥ 1 year\n\nIntact ovaries and uterus, confirmed by physical exam and imaging\n\nNormal semen analysis in male partner\n\nNo tubal or peritoneal factor contributing to infertility\n\nEffective contraception if not attempting conception\n\nWilling and able to provide informed consent\n\nExclusion Criteria:\n\nKnown thyroid disease or on thyroid medications\n\nAbnormal thyroid function tests other than subclinical hypothyroidism\n\nHyperprolactinemia\n\nPresence of other causes of infertility such as:\n\nModerate to severe male factor infertility Bilateral tubal occlusion or peritoneal factors Stage III-IV endometriosis Ovarian failure or insufficiency (high FSH or low AMH)\n\nPrevious diagnosis of any type of congenital adrenal hyperplasia\n\nUncontrolled diabetes (HbA1C \\>8%)\n\nHistory of deep vein thrombosis or thromboembolic events\n\nAny contraindication to letrozole or levothyroxine\n\nPrevious use of letrozole or levothyroxine in past 6 months\n\nCurrent or suspected pregnancy\n\nBreastfeeding\n\nInability to comply with treatment and follow-up procedures","20 Years",{"count":75,"type":20},200,[77],"NA","The goal of this randomized controlled trial is to compare letrozole alone versus letrozole plus levothyroxine for ovulation induction in infertile women with both PCOS and subclinical hypothyroidism. The main questions it aims to answer are:\n\nIs letrozole plus levothyroxine superior to letrozole alone in achieving ovulation in these patients? Does combining levothyroxine with letrozole lead to higher pregnancy and live birth rates compared to letrozole alone?\n\nParticipants will be randomized into two groups:\n\nGroup 1 will receive letrozole only, starting at 2.5 mg daily from day 3 to 7 of the menstrual cycle. The dose will be increased up to 7.5 mg if no ovulation occurs, for a maximum treatment period of 6 months or until pregnancy is achieved.\n\nGroup 2 will receive letrozole at the same doses as group 1 plus 25 mcg levothyroxine daily.",[26,80,81],"Subclinical Hypothyroidism","Female Infertility",[83,84,85,86],"Letrozole","Levothyroxine","PCOS","Subclinical hypothyroidism","2025-08-30",{"date":89,"type":31},"2025-09-03",{"date":91,"type":31},"2021-05-06",{"date":93,"type":20},"2026-06-28",{"name":95,"class":38},"Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":48,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":39},"100502253","phase-3-role-of-semaglutide-in-restoring-ovulation-in-youth-and-adults-with-polycystic-ovary-syndrome-100502253","NCT05819853","Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome","RESTORE","Inclusion Criteria\n\n1. Female\n2. Ages 12-35 years\n3. Sedentary- less than 2 hours of moderate (jogging, swimming etc.) exercise a week.\n4. Oligomenorrhea, on or off metformin, as defined per age category in the most recent 2018 PCOS international guidelines\n5. Initial BMI based on age and weight:\n\n   1. If \\\u003C18 years, initial BMI percentile ≥95\n   2. If 18-35 years, initial BMI ≥30 kg\u002Fm2 OR initial BMI ≥27 kg\u002Fm2 with at least one weight-related comorbid condition, e.g., hypertension or dyslipidemia\n   3. Must be weight stable within ±5kg in the 3 months prior to enrollment\n6. Diagnosed with PCOS per the most stringent NIH criteria with adaptation for adolescents (oligomenorrhea \\>24 months post-menarche or primary amenorrhea after age 15 years and clinical\u002F biochemical hypertestosteronemia\n7. Participants cannot be on hormonal contraception, so participants should remain abstinent or use reliable non-hormonal contraception (e.g., copper IUD) for the entire study period. For participants who receive semaglutide, they should avoid pregnancy for at least 2 months after stopping medication to avoid fetal exposure to the medication.\n8. For participants in the metformin + semaglutide group, participants must have been stable on ≥ 1500 mg of metformin a day for at least 3 months by time of screening\n\nExclusion Criteria:\n\n1. Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Family history of medullary thyroid cancer or thyroid nodule palpated by endocrinologist at screening. - Per approved drug label\n2. Use of medications known to affect insulin sensitivity: metformin (cannot have been used in the 3 months prior to screening for the untreated arm of the study), chronic oral steroids, oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, HIV medications, estrogen-containing hormonal contraception (cannot have been used in the 6 months prior to screening), progesterone-containing hormonal contraception (cannot have been used in the 3 months prior to screening). Dermal patch or vaginal ring contraception methods. Weight loss medications or stimulants. Use of other products containing other GLP-1 agonists.\n3. Weight loss medications in the last 6 months\n4. Currently pregnant or breastfeeding women. Development of pregnancy during the study period will necessitate withdrawal from the study.\n5. Severe illness requiring hospitalization within 60 days.\n6. Diabetes, defined as Hemoglobin A1C ≥6.5%\n7. Anemia, defined as Hemoglobin \\\u003C 12 mg\u002FdL\n8. Diagnosed major psychiatric or developmental disorder limiting informed consent.\n\n10\\) Known liver disease other than NAFLD, or AST or ALT \\>125 IU\u002FL. 11) Personal history of pancreatitis 12) Known renal disease of any severity or an eGFR at screening of \\\u003C45ml\u002Fmin\u002F1.73m2 13) History of severe GI disease (e.g., gastroparesis) 14) History of gallstones 15) Untreated thyroid disease 16) History of hypersensitivity to semaglutide 17) Other causes of hyperandrogenism (example: tumor, CAH) or amenorrhea (untreated thyroid disease, tumor, primary ovarian failure, prolactinoma).\n\n18\\) Active symptoms or undergoing treatment for anorexia nervosa or binging\u002Fpurging disorder 19) Desiring pregnancy in the next 12-18 months. 20) Bariatric surgery 21) Use of THC (smoking or edible) more than 3 days a week 22) Alcohol use-drinking more than 2 drinks, more than 3 days a week 23) Any potential participants who cannot\u002Fwill not commit to abstinence, use of a copper intrauterine device (IUD), or use of double barrier forms of contraception.","12 Years","35 Years",{"count":106,"type":20},80,[108],"PHASE3","Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.",[26,111],"Obese",[85,113],"semaglutide","2025-08-21",{"date":116,"type":31},"2025-08-28",{"date":118,"type":31},"2023-11-03",{"date":120,"type":20},"2028-06-30",{"name":122,"class":38},"University of Colorado, Denver",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":49,"enrollmentInfo":130,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":39},"100582322","laboratory-and-ultrasound-findings-and-response-to-letrozole-in-pcos-patients-100582322","NCT06861803","Laboratory and Ultrasound Findings and Response to Letrozole in PCOS Patients","Comparison of Laboratory and Ultrasound Findings Between Letrozole-Resistant and Letrozole-Sensitive PCOS Patients in Egypt","Inclusion Criteria:\n\n* Women aged 18-40 years.\n* Diagnosis of PCOS based on Rotterdam criteria.\n* No prior ovulation induction with letrozole.\n* Willing to follow the treatment protocol and attend follow-up visits\n\nExclusion Criteria:\n\n* Infertility due to other causes such as tubal obstruction or male factor infertility.\n* Previous ovarian surgery or use of medications that could influence ovulation.\n* Comorbidities such as uncontrolled diabetes, hyperprolactinemia, or thyroid dysfunction.",{"count":131,"type":20},138,"The goal of this observational study is to compare laboratory and ultrasound findings between letrozole-resistant and letrozole-sensitive PCOS patients in Egypt. The study will include women aged 18-40 years diagnosed with PCOS based on the Rotterdam criteria, who are undergoing ovulation induction with letrozole for the first time.\n\nThe main questions it aims to answer are:\n\nWhat are the baseline laboratory and ultrasound differences between letrozole-resistant and letrozole-sensitive PCOS patients? What factors can predict letrozole resistance in PCOS patients? Researchers will compare letrozole-resistant and letrozole-sensitive PCOS patients to determine whether specific laboratory markers and ultrasound findings can predict resistance to letrozole.\n\nParticipants will:\n\nUndergo baseline clinical, laboratory, and ultrasound assessments before starting letrozole treatment.\n\nReceive letrozole treatment with dose escalation up to 7.5 mg\u002Fday over a maximum of three cycles if ovulation is not achieved.\n\nBe monitored through serial transvaginal ultrasounds to assess follicular development.\n\nHave ovulation confirmed via mid-luteal serum progesterone levels. The study aims to improve the understanding of predictors of letrozole resistance to guide personalized ovulation induction strategies in PCOS patients.",[26],[85,135],"letrozole","2025-03-20",{"date":138,"type":31},"2025-03-21",{"date":140,"type":20},"2025-04-01",{"date":142,"type":20},"2025-12-30",{"name":144,"class":38},"Al-Azhar University",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":48,"minAge":152,"maxAge":104,"enrollmentInfo":153,"targetDuration":155,"studyType":52,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":39},"100495675","the-frequency-of-polycystic-ovary-syndrome-among-young-reproductive-females-presenting-with-hyperandrogenism-a-mixed-cohort-study-100495675","NCT05734287","The Frequency of Polycystic Ovary Syndrome Among Young Reproductive Females Presenting With Hyperandrogenism: a Mixed Cohort Study","Polycystic Ovaries in Young Girls Presenting With Hyperandrogenism","Inclusion Criteria:\n\n* Clinical hyperandrogenism\n\nExclusion Criteria:\n\n* Age less than 15 or more than 35 years.","15 Years",{"count":154,"type":20},260,"6 Months","This mixed cohort study will test the frequency of PCOS among young females presenting with one of the clinical hyperandrogenism criteria: acne, hirsutism and\u002For hair loss. Diagnosis will be based on the recent PCOS clinical, biochemical and biophysical criteria recently published \" International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS) 2018\".",[26],"2024-07-22",{"date":160,"type":31},"2024-07-23",{"date":162,"type":31},"2024-06-28",{"date":164,"type":20},"2025-08-01",{"name":166,"class":38},"Woman's Health University Hospital, Egypt",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":48,"minAge":73,"maxAge":104,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":39},"100497344","ivficsi-outcome-in-women-with-polycystic-ovary-syndrome-100497344","NCT05756023","IVF\\ICSI Outcome in Women With Polycystic Ovary Syndrome","IVF\\ICSI Outcome in Women With Polycystic Ovary Syndrome Compared With Non Polycystic Ovary Syndrome Women","Inclusion Criteria:\n\n* Oligo-ovulation or anovulation.\n* Clinical and\u002For biochemical hyper androgenesim.\n* Polycystic ovaries.\n\nExclusion Criteria:\n\n1. Androgen-secreting tumors (ovarian or adrenal).\n2. Adult-onset congenital adrenal hyperplasia.\n3. Thyroid diseases.\n4. Cushing's syndrome.\n5. Diabetes Mellitus.\n6. recurrent ICSI failure\n7. endocrine, hematologic and autoimmune disorders\n8. Non chromosomal and genetic abnormalities\n9. Major uterine anomalies, bad surgical history, sever endometriosis, , hydrosalpinx, uterine fibroids\n10. Azospermia",{"count":175,"type":20},156,[77],"Polycystic ovarian syndrome (PCOS) occurs in 5% to 10% of all women of reproductive age and 50% of women who present with sub-fertility due to anovulatory infertility . Clear diagnostic criteria for this condition were identified at the consensus meeting of the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine .",[26],"2023-10-17",{"date":181,"type":31},"2023-10-19",{"date":183,"type":31},"2023-06-01",{"date":185,"type":20},"2026-12-15",{"name":187,"class":188},"Egymedicalpedia","INDUSTRY"]